In March 2025, a federal district court issued a landmark ruling that reaffirmed a critical distinction in healthcare regulation: clinical laboratory services are not medical devices. The ruling struck down the FDA’s attempt to expand its authority over lab-developed tests…
Pediatric inflammatory bowel disease (IBD) is no longer rare, and it’s no longer acceptable to treat it with outdated tools and timelines. Pediatric IBD accounts for approximately 25% of all newly diagnosed IBD patients. Clinical experience confirms that although the…
Despite significant advancements in biologic therapy for pediatric inflammatory bowel disease (IBD), loss of response (LOR) remains a major challenge in clinical management. Infliximab (IFX) and Vedolizumab (VEDO), both widely used monoclonal antibodies, offer disease-modifying benefits, yet many pediatric patients…
Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like infliximab, has long been challenged by issues such as antibody formation, variable drug clearance, and the high costs associated with frequent dosing. In many cases, biologics are introduced only in…
Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like Infliximab (IFX), presents numerous challenges for gastroenterologists. Despite the widespread use of IFX, a significant proportion of patients experience a loss of response over time – often within the first…
TuMinimize™ enables oncologists to deliver optimal drug dosing for each patient Fort Myers, FL – June 18, 2024 — Baysient®, a leading provider of therapeutic drug monitoring (TDM) software, today announced the launch of TuMinimize™, a web-based nomogram/algorithm designed to…
A Fresh Perspective on Dosing for Biologic Agents We are excited to announce the publication of “Getting the Dose Right” - Revisiting the Topic with Focus on Biologic Agents in the Clinical Pharmacology & Therapeutics Journal, co-authored by Baysient's founder…
Inflammatory Bowel Disease (IBD) presents a significant treatment challenge for gastroenterologists worldwide. While biologic therapies have emerged as a cornerstone in managing these complex gastrointestinal conditions, their effectiveness is often hampered by a crucial factor – the variable clearance of…
In a significant stride for improving oncology treatment, Baysient® has announced its latest innovation: a groundbreaking therapeutic drug monitoring (TDM) software tailored for oncology drugs, coming soon in 2024. This TDM solution takes a Compuceutical approach, merging advanced cloud-based software…
The complexities of Psoriatic Arthritis (PsA) demand a tailored approach to treatment. With the diverse patient responses to medications, a one-size-fits-all strategy is not viable. Enter Baysient’s groundbreaking software applications, iDose® and T3®, which are redefining the therapeutic drug monitoring…
